Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
Small RCT (n=108) concludes no clinical benefit was observed at 26 weeks with addition of short-acting exenatide 10mcg tds to insulin treatment in individuals with type 1 diabetes (reduction in HbA1c of -0.3% with exenatide and -0.2% with placebo, difference −0.1%; p=0.36).
Source:
The Lancet Diabetes & Endocrinology
SPS commentary:
A related editorial discusses these findings in the context of benefits observed with exenatide in individuals with type 2 diabetes.